全文获取类型
收费全文 | 6119篇 |
免费 | 395篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 188篇 |
妇产科学 | 70篇 |
基础医学 | 979篇 |
口腔科学 | 151篇 |
临床医学 | 487篇 |
内科学 | 1121篇 |
皮肤病学 | 258篇 |
神经病学 | 868篇 |
特种医学 | 315篇 |
外科学 | 455篇 |
综合类 | 31篇 |
一般理论 | 1篇 |
预防医学 | 443篇 |
眼科学 | 152篇 |
药学 | 440篇 |
中国医学 | 13篇 |
肿瘤学 | 516篇 |
出版年
2024年 | 4篇 |
2023年 | 49篇 |
2022年 | 75篇 |
2021年 | 133篇 |
2020年 | 112篇 |
2019年 | 137篇 |
2018年 | 152篇 |
2017年 | 130篇 |
2016年 | 152篇 |
2015年 | 202篇 |
2014年 | 227篇 |
2013年 | 293篇 |
2012年 | 493篇 |
2011年 | 472篇 |
2010年 | 290篇 |
2009年 | 281篇 |
2008年 | 426篇 |
2007年 | 410篇 |
2006年 | 387篇 |
2005年 | 400篇 |
2004年 | 351篇 |
2003年 | 333篇 |
2002年 | 331篇 |
2001年 | 60篇 |
2000年 | 47篇 |
1999年 | 78篇 |
1998年 | 90篇 |
1997年 | 68篇 |
1996年 | 54篇 |
1995年 | 49篇 |
1994年 | 30篇 |
1993年 | 37篇 |
1992年 | 12篇 |
1991年 | 10篇 |
1990年 | 20篇 |
1989年 | 19篇 |
1988年 | 16篇 |
1987年 | 16篇 |
1986年 | 16篇 |
1985年 | 12篇 |
1984年 | 12篇 |
1983年 | 6篇 |
1982年 | 5篇 |
1981年 | 6篇 |
1980年 | 4篇 |
1977年 | 5篇 |
1975年 | 3篇 |
1974年 | 4篇 |
1968年 | 3篇 |
1966年 | 2篇 |
排序方式: 共有6535条查询结果,搜索用时 15 毫秒
991.
Ulrike Gottwald-Hostalek Lion Li Pablo Montenegro 《Current medical research and opinion》2016,32(10):1735-1743
Objective: The efficacy of a bisoprolol/amlodipine fixed-dose combination (FDC) in patients with essential hypertension who had not responded to bisoprolol or amlodipine monotherapy was investigated.Research design and methods: In an 18 week, multicenter, randomized, comparative phase III study (ClinicalTrials.gov identifier: NCT01977794), patients with blood pressure uncontrolled by bisoprolol or amlodipine monotherapy (5?mg OD) began treatment with bisoprolol/amlodipine FDC 5/5?mg OD. Patients with controlled blood pressure (BP) at week 6/12 continued at current FDC strength, and patients with uncontrolled BP received FDC dose uptitration (maximum dose: 10/10?mg). The primary efficacy endpoint was change in systolic blood pressure (SBP) at week 18 versus baseline (corresponding to SBP under monotherapy), and secondary endpoints included change from baseline in SBP after week 6/12 and percentage of BP-controlled patients at week 6, 12 and 18. Safety was assessed by number/types of adverse events (AEs).Results: Two hundred patients were randomized to treatment (100 with uncontrolled BP under bisoprolol and 100 under amlodipine monotherapy). Overall, 196 patients were eligible for analysis. The patient groups displayed similar mean SBP reductions from baseline by study end (bisoprolol monotherapy failure: 25.9?±?12.82?mmHg reduction; amlodipine monotherapy failure: 24.7?±?11.67?mmHg reduction; p?<?0.001 for both). Overall mean SBP decreased by 25.3?±?12.25?mmHg (p?<?0.001). Mean heart rate reductions were also observed (bisoprolol monotherapy failure: 6.6?±?9.67 bpm reduction; amlodipine monotherapy failure: 11.5?±?8.65 bpm reduction; p?<?0.001 for both). Most patients (83.2%) displayed BP control with bisoprolol/amlodipine 5/5?mg at 6 weeks. Treatment was well tolerated at all dose levels; treatment-related AEs (mostly of mild/moderate intensity) were reported by 52.5% of patients, with no severe or serious treatment-related AEs reported. As the study focused on hypertension, total cardiovascular risk was not assessed.Conclusions: Bisoprolol/amlodipine FDC therapy is associated with significant BP improvements in patients with essential hypertension following monotherapy failure. 相似文献
992.
Written case formulations in the treatment of anorexia nervosa: Evidence for therapeutic benefits 下载免费PDF全文
Karina L. Allen BA MPsych PhD Caitlin B. O'Hara PhD Savani Bartholdy MSc Beth Renwick BSc Alexandra Keyes BSc MSc Anna Lose BSc MSc Martha Kenyon MSc Hannah DeJong BA DClinPsy Hannah Broadbent MSc DClinPsy Rachel Loomes BA MSc Jessica McClelland BSc PhD Lucy Serpell BA DClinPsy PhD Lorna Richards MBChB MA Eric Johnson‐Sabine MBBS MRCGP FRCPsych Nicky Boughton MSc Linette Whitehead MSc Janet Treasure MD PhD FRCP FRCPsych OBE Tracey Wade BSc MPsych PhD Ulrike Schmidt MD PhD FRCPsych 《The International journal of eating disorders》2016,49(9):874-882
993.
Two‐year follow‐up of the MOSAIC trial: A multicenter randomized controlled trial comparing two psychological treatments in adult outpatients with broadly defined anorexia nervosa 下载免费PDF全文
Ulrike Schmidt MD PhD FRCPsych Elizabeth G. Ryan PhD Savani Bartholdy MSc Bethany Renwick Bsc Alexandra Keyes MSc Caitlin O'Hara PhD Jessica McClelland PhD Anna Lose MSc Martha Kenyon MSc Hannah Dejong ClinPsyD Hannah Broadbent PhD Rachel Loomes MSc Lucy Serpell PhD DClinPsy Lorna Richards MD Eric Johnson‐Sabine MD Nicky Boughton MSc Linette Whitehead MSc Eva Bonin MA Jennifer Beecham PhD Sabine Landau PhD Janet Treasure OBE MD PhD FRCP FRCPsych 《The International journal of eating disorders》2016,49(8):793-800
994.
995.
Suzanna G.M. Frints Friederike Hennig Roberto Colombo Sebastien Jacquemont Paulien Terhal Holly H. Zimmerman David Hunt Bryce A. Mendelsohn Ulrike Kordaß Richard Webster Margje Sinnema Omar Abdul‐Rahman Vanessa Suckow Alberto Fernndez‐Jan Kees van Roozendaal Servi J.C. Stevens Merryn V.E. Macville Salwan Al‐Nasiry Koen van Gassen Norbert Utzig Suzanne M. Koudijs Lesley McGregor Saskia M. Maas Diana Baralle Abhijit Dixit Peter Wieacker Marcus Lee Arthur S. Lee Elizabeth C. Engle Gunnar Houge Gyri A. Gradek Andrew G.L. Douglas Cheryl Longman Shelagh Joss Danita Velasco Raoul C. Hennekam Hiromi Hirata Vera M. Kalscheuer 《Human mutation》2019,40(12):2270-2285
Pathogenic variants in the X‐linked gene ZC4H2, which encodes a zinc‐finger protein, cause an infrequently described syndromic form of arthrogryposis multiplex congenita (AMC) with central and peripheral nervous system involvement. We present genetic and detailed phenotypic information on 23 newly identified families and simplex cases that include 19 affected females from 18 families and 14 affected males from nine families. Of note, the 15 females with deleterious de novo ZC4H2 variants presented with phenotypes ranging from mild to severe, and their clinical features overlapped with those seen in affected males. By contrast, of the nine carrier females with inherited ZC4H2 missense variants that were deleterious in affected male relatives, four were symptomatic. We also compared clinical phenotypes with previously published cases of both sexes and provide an overview on 48 males and 57 females from 42 families. The spectrum of ZC4H2 defects comprises novel and recurrent mostly inherited missense variants in affected males, and de novo splicing, frameshift, nonsense, and partial ZC4H2 deletions in affected females. Pathogenicity of two newly identified missense variants was further supported by studies in zebrafish. We propose ZC4H2 as a good candidate for early genetic testing of males and females with a clinical suspicion of fetal hypo‐/akinesia and/or (neurogenic) AMC. 相似文献
996.
Christina Ganster Catharina Müller‐Thomas Claudia Haferlach Corinna Strupp Kiyoyuki Ogata Ulrich Germing Barbara Hildebrandt Mar Mallo Michael Lübbert Christel Müller Francesc Sol Katharina S. Gtze Peter Vandenberghe Gudrun Ghring Tilman Steinmetz Nicolaus Krger Uwe Platzbecker Ulrike Sling Sophie Raynaud Katayoon Shirneshan Julie Schanz Detlef Haase 《Genes, chromosomes & cancer》2019,58(10):689-697
The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the new comprehensive cytogenetic scoring system for MDS, chromosome 7 anomalies are no longer generally assigned to poor risk features but are thoroughly separated. However, der(1;7)(q10;p10), hereinafter der(1;7), is merged into the group labeled “any other single” and belongs to the intermediate risk group, just by definition due to lack of adequate clinical data. The aim of our international collaborative was to clarify the “real” prognostic impact of der(1;7) on a homogenous and well‐documented data base. We performed detailed analysis of 63 MDS patients with isolated der(1;7) constituting the largest cohort hitherto reported. Furthermore, clinical data are compared with those of patients with isolated del(7q) and isolated monosomy 7. Median overall survival (OS) of patients with der(1;7) is 26 months (hazard ratio (HR) 0.91 for del(7q) vs der(1;7) and 2.53 for monosomy 7 vs der(1;7)). The der(1;7) is associated with profound thrombocytopenia most probably causing the reduced OS which is in striking contrast to the low risk for AML transformation (HR 3.89 for del(7q) vs der(1;7) and 5.88 for monosomy 7 vs der(1;7)). Molecular karyotyping indicates that der(1;7) is generated in a single step during mitosis and that a chromosomal imbalance rather than a single disrupted gene accounts for malignancy. Thus, the current cytogenetic scoring system assigning isolated der(1;7) to the intermediate risk group is now confirmed by a sufficient data set. 相似文献
997.
P Heider M Hofmann P C Maurer S von Sommoggy 《European journal of vascular and endovascular surgery》1999,18(1):43-47
OBJECTIVE: to study the primary patency rates of angioscopically controlled thromboendarterectomies of the superficial femoral artery. DESIGN: prospective open study. METHODS: between 1990 and 1995, femoropopliteal thromboendarterectomies were performed in 63 patients (41 male, 22 female). Postoperative follow up was performed at 3- to 6-month intervals using non-invasive pressure measurements plus IVDSA at 1 year. RESULTS: eight patients were not evaluable, leaving 55 patients eligible for follow-up analysis. Postoperative complications (arteriovenous fistulas, false aneurysms) were observed in 5.4% of patients. Immediate perioperative occlusions occurred in 7.3%, early occlusions in 21.8% and late occlusions in 16.4% of all cases. The mean follow-up was approximately 57 months. The mean primary patency rate at 5 years was 44.5% (28 patients with the superficial femoral artery still open). Six patients died during the follow-up period. CONCLUSIONS: in contrast to the very positive reports found in recent literature, this prospective study shows a lower five-year patency rate for semi-closed femoropopliteal thromboendarterectomy than for bypass grafting. Thromboendarterectomy cannot be considered as a standard procedure in revascularisation of the femoropopliteal region. 相似文献
998.
O Sezer P Schmid M Shweigert U Heider J Eucker H Harder P Sinha H Radtke K Possinger 《Bone marrow transplantation》1999,23(9):967-969
In a patient with nephrotic syndrome, renal biopsy revealed AL amyloid deposits. Monoclonal lambda light chains were identified in serum and urine. A low percentage of monoclonal plasma cells was detected in the bone marrow. The patient received four cycles of VAD and subsequent high-dose chemotherapy (HDCT) with melphalan (200 mg/m2) followed by autologous peripheral blood stem cell transplantation. Proteinuria rapidly diminished during chemotherapy. Three months after HDCT, the patient has no edema, and no signs of plasma cell dyscrasia are currently detectable. Using VAD before starting HDCT may improve the condition of patients with amyloidosis and reduce transplantation-related morbidity and mortality. 相似文献
999.
Ulrike Ehmer Camilla J. F. Tulloch William R. Proffit Ceib Phillips 《Journal of orofacial orthopedics》1999,242(1):392-408
The University of North Carolina at Chapel Hill has established an extensive randomized trial to evaluate early treatment of Class-II/1 cases. As presented in this part of the study, a German treatment group was selected in parallel, based on identical prospective criteria, in the context of international cooperation with the Westfälische Wilhelms-Universität, Münster. One essential aspect of this study is the degree to which initially comparable groups can be established by careful alignment of selection criteria and of compilation and analysis of diagnostic records.Nine skeletal analysis parameters initially indicated that it is possible to select very similar though not absolutely identical groups in the context of international cooperation. The further results of the initial 15-month phase comprising functional orthodontic treatment in severe Class-II/1 cases showed significant mandibular effects in both treatment groups (USA UNC, Chapel Hill: modified Balters appliance; Germany WWU Münster: U-bow activator Type I). The groups were compared to a randomized control group with similar untreated malocclusions, established at Chapel Hill (USA UNC, Chapel Hill). 相似文献
1000.
Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection 总被引:13,自引:0,他引:13 下载免费PDF全文
Ulrike Protzer Michael Nassal Pei-Wen Chiang Michael Kirschfink Heinz Schaller 《Proceedings of the National Academy of Sciences of the United States of America》1999,96(19):10818-10823
Hepatitis B viruses specifically target the liver, where they efficiently infect quiescent hepatocytes. Here we show that human and avian hepatitis B viruses can be converted into vectors for liver-directed gene transfer. These vectors allow hepatocyte-specific expression of a green fluorescent protein in vitro and in vivo. Moreover, when used to transduce a type I interferon gene, expression of interferon efficiently suppresses wild-type virus replication in the duck model of hepatitis B virus infection. These data suggest local cytokine production after hepatitis-B-virus-mediated gene transfer as a promising concept for the treatment of acquired liver diseases, including chronic hepatitis B. 相似文献